On Jun. 17, 2020, Innovation Pharma reported receiving data from ongoing laboratory testing being conducted at a U.S. Regional Biocontainment Laboratory (RBL).

Brilacidin exhibited a statistically significant (p<0.0001) and potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human lung epithelial cell lineﾗreducing viral load by 95 percent and by 97 percent, compared to control, at two therapeutic concentrations tested. Based on a CC50 valueﾗthe concentration of drug at which 50 percent of cells maintain viabilityﾗBrilacidin was also shown to be non-cytotoxic in the lung cell line.